23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
23:15 , Jul 15, 2019 |  BC Extra  |  Company News

Management tracks: GSK, Orphazyme, Kymera and more

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to confirm news reports stating it will appoint Jonathan Symonds as chairman to succeed Philip Hampton, who has served in the role since 2015. The Financial Times and Bloomberg, citing...
21:45 , Jul 12, 2019 |  BC Extra  |  Company News

July 12 Company Quick Takes: Emflaza could be cost-effective for DMD at highest threshold; plus Darzalex, Skyrizi, Forxiga

ICER gives Emflaza pricing more leeway in updated report  The Institute for Clinical and Economic Review released an updated evidence report on Duchenne muscular dystrophy therapies that increased its range of acceptable prices at which...
21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
22:56 , Jun 28, 2019 |  BC Extra  |  Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

EMA's CHMP issued a basket of opinions Friday, including a negative opinion for Amgen's osteoporosis drug Evenity, and a recommendation for La Jolla's hypotension therapy Giapreza. The agency recommended against approval of Evenity romosozumab-aqqg from...
01:21 , Jun 28, 2019 |  BC Extra  |  Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

Four companies have debuted with upsized NASDAQ offerings in the past 24 hours, including the year's largest, to continue June's torrid IPO pace as 1H19 draws to a close. BridgeBio, Adaptive and Morphic all saw...
21:57 , Jun 27, 2019 |  BC Innovations  |  Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...